CTRI/2018/03/012679
Not yet recruiting
Phase 2
An open label prospective phase II clinical study to evaluate efficacy and safety of panchendriyavardhan tail in the insomnia
Aushadhi Bhavan0 sites0 target enrollmentStarted: TBDLast updated:
Overview
- Phase
- Phase 2
- Status
- Not yet recruiting
- Sponsor
- Aushadhi Bhavan
Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
Inclusion Criteria
- •Healthy volunteers suffering from insomnia and willing to give written informed consent
Exclusion Criteria
- •Volunteers with chronic illness
Investigators
Similar Trials
Active, not recruiting
Phase 1
En åben fase II undersøgelse af sikkerhed, tolerabilitet, højeste tolerable dosis og anti-tumor effekt af SCO-101 i kombination med FOLFIRI som en sikker og effektiv behandling af patienter med udbredt kolorektalkræft, der har udviklet behandlingsresistens overfor behandling med FOLFIRIMetastatic or advanced colorectal cancer (mCRC) with acquired resistance to chemotherapyMedDRA version: 27.0Level: LLTClassification code 10052362Term: Metastatic colorectal cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2019-003779-20-DKScandion Oncology A/S79
Active, not recruiting
Phase 1
An open phase II study of safety, tolerability, highest tolerable dose and anti-tumor effect of SCO-101 in combination with FOLFIRI as a safe and effective treatment of patients with widespread colorectal cancer who has developed treatment resistance to treatment with FOLFIRIEUCTR2019-003779-20-ESScandion Oncology A/S35
Active, not recruiting
Phase 1
An open phase II study of safety, tolerability, highest tolerable dose and anti-tumor effect of SCO-101 in combination with FOLFIRI as a safe and effective treatment of patients with widespread colorectal cancer who has developed treatment resistance to treatment with FOLFIRIEUCTR2019-003779-20-DEScandion Oncology A/S35
Active, not recruiting
Not Applicable
Prospective, randomized, open label phase II study to assess efficacy and safety of Macugen® (pegaptanib 0.3 mg intravitreal injections) plus panretinal photocoagulation (PRP) and PRP (monotherapy) in the treatment of patients with high risk proliferative diabetic retinopathy. -Proliferative Diabetic Retinopathy.MedDRA version: 12.0Level: LLTClassification code 10036857Term: Proliferative diabetic retinopathyEUCTR2009-016760-36-PTAIBILI
Completed
Phase 2
To evaluate the safety and efficacy of Arnophyte Cream in subjects with HerpesHealth Condition 1: null- Early signs & symptoms of recurrent HSV-2Health Condition 2: B008- Other forms of herpesviral infectionsCTRI/2018/01/011171Piramal Enterprises Limited40